Key Highlights
- AbbVie approaches completion of a $10.9 billion cash acquisition for Apogee Therapeutics (APGE)
- Deal represents approximately 60% premium over Apogee’s $90.38 share price from June 18
- JPMorgan maintains Buy rating on ABBV, describing acquisition as strategically sound
- Apogee’s primary asset, zumilokibart, positions itself as potential Dupixent competitor for atopic dermatitis
- ABBV shares declined more than 2% Friday; APGE climbed approximately 2%
AbbVie stands on the verge of securing Apogee Therapeutics, a clinical-stage biotechnology firm, through an all-cash transaction valued at nearly $10.9 billion. The proposed purchase price represents about a 60% markup from Apogee’s June 18 closing value of $90.38. Shares of ABBV slipped more than 2% Friday, whereas APGE advanced roughly 2% following the disclosure.
Reuters reports that a formal announcement may arrive as soon as Monday, June 22, though both companies have remained silent regarding the negotiations.
This transaction would represent AbbVie’s most substantial acquisition since the $63 billion Allergan deal closed in 2019. However, unlike Allergan which brought established products and revenue streams, Apogee currently operates without any marketed therapies.
Apogee specializes in developing antibody-based therapies targeting inflammatory conditions such as atopic dermatitis, asthma, and chronic obstructive pulmonary disease. The company’s entire development portfolio centers on its primary candidate: zumilokibart.
Zumilokibart works by targeting interleukin-13, a cytokine responsible for driving inflammatory responses in atopic dermatitis. Clinical trial results suggest the therapy may only need administration twice annually, a dramatic reduction from the up to 26 yearly injections required by certain current treatments.
JPMorgan Supports Deal Rationale
JPMorgan equity analyst Chris Schott maintained his Buy recommendation on ABBV following the acquisition reports. He characterized the transaction as strategically advantageous, highlighting AbbVie’s extensive immunology expertise as crucial for successfully commercializing zumilokibart upon potential approval.
Schott further emphasized that zumilokibart stands positioned to compete head-to-head with Dupixent, the market-leading treatment jointly marketed by Sanofi and Regeneron that currently commands the atopic dermatitis space.
His assessment suggests AbbVie would implement an extensive development strategy for the compound, while the acquisition bolsters the company’s late-stage asset portfolio — an area under significant investor scrutiny.
ABBV holds a Strong Buy consensus rating on TipRanks, backed by 16 Buy recommendations and 5 Hold ratings across the last three months. The average price target stands at $254.71, suggesting approximately 17.65% potential gain.
Pipeline Challenges Drive M&A Strategy
AbbVie’s leading immunology trio — Skyrizi, Rinvoq, and Humira — collectively delivered $30.4 billion in 2025 revenue, representing 14% year-over-year growth. However, Humira faces ongoing erosion from biosimilar alternatives.
While Skyrizi and Rinvoq currently compensate for Humira’s decline, this growth trajectory cannot sustain indefinitely. AbbVie has shifted toward acquiring early-stage assets instead of allowing them to progress through later development stages.
In 2024, the pharmaceutical giant committed up to $2.1 billion for Capstan Therapeutics, a Phase 1-stage autoimmune cell therapy company. The Apogee transaction represents a significantly larger and earlier-stage investment than previous acquisitions.
Apogee had already arranged up to $1.3 billion in funding from Blackstone Life Sciences this past May to support a Phase 3 clinical trial for zumilokibart. AbbVie essentially purchases entry into that pivotal trial before any regulatory determination occurs.
Prior to deal speculation, Apogee maintained a market capitalization around $6.8 billion, having risen nearly 20% year-to-date. AbbVie’s nearly $11 billion offer clearly prices in future promise rather than existing commercial products.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
